Daniël Jan Ellens
Chairman of the Board, Chairman of the Remuneration Committee and the Nomination Committee
Daan J. Ellens (1948) has been member of the Board since 2005, and served as Chairman in 2007-2012, and Vice Chairman until April 2013. He is regarded as an independent board member.
Daan J. Ellens is Chairman of the Supervisory Board of Prosensa B.V. (The Netherlands), Hybrigenics SA (France) and Kreatech Holding B.V. (The Netherlands). Previously, he has held positions as CEO of Rhein Biotech N.V. (resigned December 2004), COO of Berna Biotech AG (resigned December 2004), CEO of Green Cross Vaccine Corporation Ltd (resigned December 2001), Member of the Supervisory Board of Life Sciences Partners (resigned May 2004), and as Venture Partner at Life Science Partners (resigned December 2012).
Daan J. Ellens holds a PhD in Molecular Biology from State University Utrecht in the Netherlands and an MBA from the University of Eindhoven, the Netherlands.
Vice Chairman of the Board
Jørgen Lindegaard (1948) has been member of the Board since 2011, and became Chairman in 2012 until April 2013. He is regarded as an independent board member.
Jørgen Lindegaard had more than 25 years of experience in the telecommunications industry, before he was appointed CEO of SAS in 2000. He left the company in 2006 to become the CEO of ISS A/S, from where he resigned in 2010. He serves as Chairman of the Board of AVT Business School A/S (Denmark), Deducta A/S (Denmark), Scania (Denmark), Scania (Norway), JL Rungsted Holding (Denmark), Trifina Holding ApS (Denmark), and K/S Vimmelskaftet 39-41 (Denmark). He is Deputy Chairman of the Board of IT University of Copenhagen (Denmark) as well as a member of the Board of Efsen Engineering A/S (Denmark).
Jørgen Lindegaard holds a Master of Engineering (Electronics) from Technical University in Denmark.
Peter Benson (1955) has been member of the Board since 2007, and served as Vice Chairman 2010-2011. He is regarded as an independent board member.
Peter Benson is Managing Partner of Sunstone Capital and earlier was Partner and Head of Life Science Ventures from 2003. Prior to founding Sunstone Capital, he spent 20 years in the life science industry, including as President of Pharmacia Hospital Care. He also served on a number of Life Science boards, including the currently public listed companies Biogaia (Sweden), Ortivus (Sweden), Cellavision AB (Sweden) and Optovent AB (Sweden). Mr. Benson serves as a member of the Board of Asante Solutions Inc. (USA), Virogates A/S (Denmark), Alligator AB (Sweden) and Imix Holding AB (Sweden).
Peter Benson holds a Bachelor of Business Administration from the University of Lund and a M.A. in Economics from the University of California.
Board member, Chairman of the Clinical and Scientific Advisory Board
Alain Munoz (1949) has been member of the Board since 2005 (resigned in 2006, and re-elected in 2007), and is not an independent member.
Alain Munoz is CEO and founder of Amistad Pharma S.A.S. (France) and Science, Business and Management SARL (France), and has over 20 years of experience in the pharmaceutical industry at senior management level. Within the Sanofi Group he served as SVP for International development (France) and in Fournier Laboratories as SVP for the Pharmaceutical division (France). He is a member of the Board of Vivalis SA (France), Auris medical AG (Switzerland), Medesis Pharma SA (France) and Hybrigenics SA (France).
Alain Munoz holds an MD in Cardiology and Anaesthesiology from the Hospital Pitié-Salpétrière, Paris. He has numerous publications and has been a member of the scientific committee of the French Drug Agency.
Michael J. Owen
Michael J. Owen (1951) was elected to the Board of Zealand in 2012, and is regarded as an independent board member.
Michael J. Owen is a co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on the immune system. He has more than 150 publications and membership of the European Molecular Biology Organisation and Fellowship of the Academy of Medical Sciences. He is a member of the Board of Ossianix, Inc. (USA) and BliNK Therapeutics (UK).
Michael J. Owen holds a PhD in amino acid transport in trypanosomes from Cambridge University, and a BA in Biochemistry from Keble College, Oxford University.
Florian Reinaud (1973) has been member of the Board since 2010, and is regarded as an independent board member.
Florian Reinaud serves as Partner at CDC Innovation (France), and before joining CDC, he was the CFO of DBV Technologies (France). Prior to that, he worked at Apax Partners (France). Previously he was an equity analyst at Schroder Salomon Smith Barney (Citigroup) covering the pan-European medtech and healthcare services sectors. He also has worked as a doctor in the UK’s National Health Service (Accident & Emergency and Internal Medicine). He serves as a member of the Board of FAB Pharma SAS (France), Kuros Biosurgery AG (Switzerland), and as observer at the Board of Orthopaedic Synergy Inc. (USA).
Florian Reinaud holds a medical degree from Imperial College London and a BA (Hons) in Physiology from Oxford University.
Jutta af Rosenborg
Board member, Chairman of the Audit Committee
Jutta af Rosenborg (1958) has been member of the Board since 2011, and is regarded as an independent board member.
Jutta af Rosenborg has a background as CFO, Executive Vice President of the global pharmaceutical company ALK-Abelló A/S. Previously she had leading positions at Chr. Hansen A/S, and in Deloitte’s auditing and consultancy department together with experience in honorary positions with a number of committees and councils. She is a member of the Board of Directors of Auriga Industries A/S (Denmark) and Carnegie WorldWide Investment Fund (Denmark).
Jutta af Rosenborg holds a degree as State-Authorised Public Accountant and MSc (Business Administration and Auditing) from the Copenhagen Business School.
Hanne Heidenheim Bak
Board member/employee elected
Hanne H. Bak (1953) has been member of the Board since 2012. Hanne H. Bak is Senior Project Director at Zealand. She has more than 25 years of experience in the pharmaceutical industry, having worked in international project management, and with partnership strategy and accredited educational concepts for specialists and patients. Before joining Zealand in 2006, Hanne H. Bak was Executive Director at the Lundbeck Institute, and she has held positions also in Lundbeck A/S and Dumex A/S. Hanne H. Bak holds a MSc (Pharm) from the Danish University of Pharmaceutical Sciences.
Board member/employee elected
Helle Størum (1967) has been member of the Board since 2008. Helle Størum is Business Development Manager at Zealand. She has more than 17 years of experience in the pharmaceutical industry, working with business development, market research, competitive Intelligence, forecasting and financial evaluations. She has previously been employed at Nycomed A/S and H. Lundbeck A/S. Helle Størum holds a MSc (Economics) from University of Southern Denmark and a Diploma in Basic Pharmaceutical Medicine.
Board member/employee elected
Christian Thorkildsen (1968) has been member of the Board since 2005. Christian Thorkildsen is Project Director at Zealand. He holds an MSc (Pharm) from the Danish University of Pharmaceutical Sciences.